KPV: What the Evidence Actually Shows

Grade CPending FDA rulemaking

Status first, and one detail worth knowing

KPV is not currently legal to compound. It was recommended by the FDA advisory committee in July 2026, but formal rulemaking has to complete.

The detail: FDA staff reported that none of the studies they found during their evaluation were in humans. The committee recommended it anyway. That is not a reason to dismiss the compound, but it is a reason to be honest about what is and is not known.

The short version

A three amino acid fragment (lysine, proline, valine) of alpha-MSH.
Studied for anti-inflammatory effects, particularly in gut and skin models.
No human studies were identified in FDA's own review.
Frequently added to recovery blends, which is where most people encounter it.
Pending rulemaking. Not available.

What it is

KPV is the C-terminal tripeptide of alpha-melanocyte stimulating hormone. The parent hormone has a range of activities including pigmentation; the KPV fragment appears to retain anti-inflammatory activity without the pigmentation effects, which is what makes it interesting.

What the research shows

In cell culture and rodent models of colitis, KPV has been reported to reduce inflammatory signalling, including through NF-kB pathways. Some work has looked at oral and topical delivery.

That is the whole of it. There is no human trial base, which FDA said plainly during the July 2026 review.

What this will not do

It will not come with human evidence. None was found by FDA's own reviewers.
It will not replace treatment for inflammatory bowel disease or any diagnosed condition.
It will not be available until rulemaking completes.

Full library · Safety and sourcing · Reconstitution calculator · Compound index